Skip to content
Triangle logo TriangleGet started
← Full study record

NCT02947685 · OUTCOME

Overall Survival (OS)

Randomized, Open Label, Clinical Study of the Targeted Therapy, Palbociclib, to Treat Metastatic Breast Cancer · Source last updated 2026-02-12

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

Measure
MEDIAN
Unit
Months
Interval / dispersion
95% Confidence Interval
Time frame
7 years 3 months

What was measured

Defined as time from date of randomization to date of death due to any cause

Groups in this outcome

Arm A

Palbociclib 125 mg daily and AntiHER2 Therapy (trastuzumab/pertuzumab) q3wks + Endocrine Therapy (letrozole, anastrozole, exemstane OR fulvestratnt)

Arm B

AntiHER2 Therapy (trastuzumab/pertuzumab) q3wks + Endocrine Therapy (letrozole, anastrozole, exemstane OR fulvestrant)

Group identifiers and denominators belong to this outcome only. They may differ in another outcome or in safety reporting.

Analysis denominator · Participants

GroupSource count
Arm A261
Arm B257

Reported measurements

Source class 1
Values in Months · Interval/dispersion: 95% Confidence Interval
GroupValueSpreadLowerUpperComment
Arm ANANot reported71.6NAToo few events occurred to calculate the median and upper CI limit
Arm B77Not reported72NAToo few events occurred to calculate the upper CI limit
Complete source fields
classes
  1. categories
    1. measurements
      1. comment
        Too few events occurred to calculate the median and upper CI limit
        group Id
        OG000
        lower Limit
        71.6
        upper Limit
        NA
        value
        NA
      2. comment
        Too few events occurred to calculate the upper CI limit
        group Id
        OG001
        lower Limit
        72
        upper Limit
        NA
        value
        77
denoms
  1. counts
    1. group Id
      OG000
      value
      261
    2. group Id
      OG001
      value
      257
    units
    Participants
description
Defined as time from date of randomization to date of death due to any cause
dispersion Type
95% Confidence Interval
groups
  1. description
    Palbociclib 125 mg daily and AntiHER2 Therapy (trastuzumab/pertuzumab) q3wks + Endocrine Therapy (letrozole, anastrozole, exemstane OR fulvestratnt)
    id
    OG000
    title
    Arm A
  2. description
    AntiHER2 Therapy (trastuzumab/pertuzumab) q3wks + Endocrine Therapy (letrozole, anastrozole, exemstane OR fulvestrant)
    id
    OG001
    title
    Arm B
param Type
MEDIAN
reporting Status
POSTED
time Frame
7 years 3 months
title
Overall Survival (OS)
type
SECONDARY
unit Of Measure
Months

Download exact source JSON → · Snapshot ctgov-results-191f4516d4760045304b24a0

Preserved source evidence · Not medical advice